Literature DB >> 9513537

[High-dose methylprednisolone-containing chemotherapy in advanced invasive thymoma--report of three cases].

T Suda1, S Sugimura, Y Hattori, H Sugimura, Y Kobayashi, R Hoshino.   

Abstract

During the period from May, 1995 to August, 1996, three patients with Stage III or IVa invasive thymoma received chemotherapy consisting of cisplatin, doxorubicin and methylprednisolone (1000 mg on days 1 through 5, and 500 mg on days 6 and 7). The first case, a 55-year-old woman, who underwent extended thymectomy 7 years ago, was found to have a recurrent tumor in the left pleural cavity. The second case, a 38-year-old man, who had first operation 3 years ago, developed recurrent tumor in the right pleural cavity. These two patients were treated with the above regimen as the primary mode of therapy. The third case, a 61-year-old woman, had a thymoma with direct invasion to right upper lobe. The same chemotherapy regimen was employed as the induction chemotherapy. All patients showed a major response to treatment with only a small amount of tumor remaining. The effectiveness of chemotherapy in the treatment of malignant tumors has been recently reported to be at least partly due to induction of apoptosis. Steroids are known to induce apoptosis in normal thymic cells, and thus steroid in chemotherapy regimen against invasive thymoma may enhance the effect of anti-cancer drugs through the induction of apoptosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9513537     DOI: 10.1007/bf03217734

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  10 in total

1.  Chemotherapy of malignant thymoma. Case report and review of the literature.

Authors:  E Hu; J Levine
Journal:  Cancer       Date:  1986-03-15       Impact factor: 6.860

2.  Response of thymoma to steroids.

Authors:  J D Green; W H Forman
Journal:  Chest       Date:  1974-01       Impact factor: 9.410

3.  Chemotherapy for invasive thymoma. A 13-year experience.

Authors:  A Fornasiero; O Daniele; C Ghiotto; M Piazza; L Fiore-Donati; F Calabró; F Rea; M V Fiorentino
Journal:  Cancer       Date:  1991-07-01       Impact factor: 6.860

4.  Involvement of protein kinase C-epsilon in glucocorticoid-induced apoptosis in thymocytes.

Authors:  M Iwata; R Iseki; K Sato; Y Tozawa; Y Ohoka
Journal:  Int Immunol       Date:  1994-03       Impact factor: 4.823

5.  Thymoma: results with complete resection and adjuvant postoperative irradiation in 141 consecutive patients.

Authors:  K Nakahara; K Ohno; J Hashimoto; H Maeda; S Miyoshi; M Sakurai; Y Monden; Y Kawashima
Journal:  J Thorac Cardiovasc Surg       Date:  1988-06       Impact factor: 5.209

6.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.

Authors:  S W Lowe; H E Ruley; T Jacks; D E Housman
Journal:  Cell       Date:  1993-09-24       Impact factor: 41.582

7.  Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group.

Authors:  P J Loehrer; K Kim; S C Aisner; R Livingston; L H Einhorn; D Johnson; R Blum
Journal:  J Clin Oncol       Date:  1994-06       Impact factor: 44.544

8.  Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline.

Authors:  S Fan; M L Smith; D J Rivet; D Duba; Q Zhan; K W Kohn; A J Fornace; P M O'Connor
Journal:  Cancer Res       Date:  1995-04-15       Impact factor: 12.701

9.  Follow-up study of thymomas with special reference to their clinical stages.

Authors:  A Masaoka; Y Monden; K Nakahara; T Tanioka
Journal:  Cancer       Date:  1981-12-01       Impact factor: 6.860

10.  Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3.

Authors:  M M Borner; C E Myers; O Sartor; Y Sei; T Toko; J B Trepel; E Schneider
Journal:  Cancer Res       Date:  1995-05-15       Impact factor: 12.701

  10 in total
  1 in total

Review 1.  The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug?

Authors:  Liliana Montella; Margaret Ottaviano; Rocco Morra; Erica Pietroluongo; Pietro De Placido; Marianna Tortora; Chiara Sorrentino; Gaetano Facchini; Sabino De Placido; Mario Giuliano; Giovannella Palmieri
Journal:  Cancers (Basel)       Date:  2022-02-02       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.